Drug intelligence / Profile preview

saroglitazar

Development stage: Phase 4
Lead developer: Zydus Lifesciences
Modality: Small Molecules
Administration: Oral

Overview

Saroglitazar is a dual peroxisome proliferator-activated receptor (PPAR) agonist, specifically targeting PPARα and PPARγ. It is used to treat diabetic dyslipidemia, hypertriglyceridemia, and type 2 diabetes mellitus, particularly in cases not controlled by statin therapy. Additionally, it is approved for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in India. Saroglitazar helps manage high cholesterol and blood sugar levels by reducing triglycerides, LDL cholesterol, and VLDL cholesterol while increasing HDL cholesterol. It is developed by Zydus Lifesciences.

Brand names: LipaglynBilypsaLINVAS
Other names: saroglitazarum

Targets

PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)

Beyond the preview

Go deeper on saroglitazar.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on saroglitazar.

Explore the full profile